STO · ISOFOL.ST
Isofol Medical AB (publ)
SEK 1.19+SEK 0.04 (+3.66%)
Isofol Medical AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 4.96% below the high.
Loading market information…
STO · INIT.ST · SEK
Stock price, earnings
Quote as of Oct 29, 2026, 03:03 PM UTC. Cached market data; not a live quote.
One-year closing-price history · SEK. Historical prices are not a forecast.
Initiator Pharma A/S’s quoted price sits in the lower half of its reported 52-week range, 42.74% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Initiator Pharma A/S’s next earnings report is currently expected on Nov 20, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Initiator Pharma A/S’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Initiator Pharma A/S is a clinical-stage life sciences firm dedicated to discovering therapeutic solutions for critical unmet medical needs affecting the central and peripheral nervous systems. Its development pipeline features several clinical-phase compounds: IP2018, a monoamine reuptake inhibitor aimed at psychogenic erectile dysfunction; IPED2015, designed to address organic erectile dysfunction; and IPTN2021, an orphan drug candidate for severe neuropathic pain. Additionally, the company holds early-stage assets, including IPNP2015 for chronic pain management and IPDP2015 for depression. Established in 2016, Initiator Pharma A/S maintains its headquarters in Copenhagen, Denmark.
Latest available per-share figures in SEK. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:27 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
SEK 1.19+SEK 0.04 (+3.66%)
Isofol Medical AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 4.96% below the high.
SEK 3.17+SEK 0.12 (+3.93%)
Bio-Works Technologies AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 36.35% below the high.
SEK 2.12+SEK 0.07 (+3.41%)
IRLAB Therapeutics AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 23.74% below the high.
SEK 14.35+SEK 0.10 (+0.7%)
Lipum AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 28.07% below the high.
SEK 4.79+SEK 0.34 (+7.64%)
SenzaGen AB’s quoted price sits in the lower half of its reported 52-week range, 29.97% below the high.
SEK 0.28-SEK 0.01 (-3.81%)
iZafe Group AB’s quoted price sits in the lower half of its reported 52-week range, 65.25% below the high.
SEK 0.38+SEK 0.00 (+1.08%)
Alzinova AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 81.86% below the high.
SEK 0.24+SEK 0.01 (+2.13%)
KDventures AB’s quoted price sits in the lower half of its reported 52-week range, 82.14% below the high.
